Oral-Systemic Link: Page 55

Analysis: Widespread cancer screening does little to prevent deaths

By Donna Domino

Screening for diseases that can lead to death typically does not prolong life substantially, according to a controversial new meta-analysis in the International Journal of Epidemiology. A few screening tests may avert some deaths, but even then it is difficult to document an improvement in overall survival, the researchers found.

January 20, 2015

Oral HPV infection more likely to persist in older men

By DrBicuspid.com staff writers

Oral infection with the human papillomavirus (HPV) type most frequently linked to HPV-related head and neck cancers is more likely to persist at least a year or more in men older than 45, according to a new study published in Cancer Prevention Research.

January 15, 2015

DrBicuspid.com Oral Cancer & Diagnostics Insider: Heavy smokers should be checked for HNC

By Donna Domino

January 14, 2015

Scynexis receives FDA fast-track designation for antifungal formulation

By DrBicuspid.com staff writers

Scynexis has been granted fast-track designation by the U.S. Food & Drug Administration (FDA) for the oral formulation of SCY-078, the company's novel antifungal product in development for the treatment of invasive Candidiasis, including candidemia and invasive aspergillosis.

January 11, 2015

Dental Health & Wellness to administer dental benefits for Fla. Medicaid

By DrBicuspid.com staff writers

Sunshine Health announced that Dental Health & Wellness is Sunshine's new dental benefits manager. Dental Health & Wellness is partnering with Sunshine to administer dental benefits for more than 410,000 Medicaid members in Florida.

January 8, 2015

Selecta Biosciences gets $3.2M grant to develop immunotherapy

By DrBicuspid.com staff writers

Selecta Biosciences has received a $3.2 million grant from the Skolkovo Foundation to develop an immunotherapy to treat cancers caused by the human papilloma virus, such as cervical, head, and neck cancers.

December 23, 2014

Forward Science donates 3rd OralID to Philadelphia foundation

By DrBicuspid.com staff writers

Forward Science Technologies has donated a third OralID device as part of its OralID Facebook Charity Campaign to St. Christopher's Foundation for Children in Philadelphia.

December 22, 2014

Robotic surgery technique treats previously inoperable HNC

By DrBicuspid.com staff writers

Researchers from the University of California, Los Angeles have advanced a robotic surgery technique to treat previously inoperable head and neck cancer (HNC) tumors, according to a new report in the journal Head & Neck.

December 22, 2014

Study: Experienced radiation centers have better outcomes for HNC

By DrBicuspid.com staff writers

Experienced radiation centers have better outcomes for patients with head and neck cancer (HNC), according to a new study in the Journal of Clinical Oncology. Researchers found that patients who underwent radiation therapy at treatment centers with less experience had higher cancer recurrence and poorer overall survival.

December 14, 2014

FDA approves Gardasil 9 vaccine for 9 HPV types

By DrBicuspid.com staff writers

The U.S. Food and Drug Administration (FDA) has approved the Gardasil 9 vaccine for preventing certain diseases caused by nine types of human papillomavirus (HPV).

December 10, 2014

Vigiliant marks milestone certification

By DrBicuspid.com staff writers

Vigilant Biosciences has received International Organization for Standardization (ISO) 13485:2003 certification, an internationally recognized quality standard for medical devices.

December 10, 2014

Antacids linked to better survival in HNSCC

By Donna Domino

Patients with head and neck squamous cell carcinoma (HNSCC) who took antacid medicines to control acid reflux had better overall survival in a new study, published in Cancer Prevention Research.

December 10, 2014

Previous Page

Page 55 of 151

Next Page